A number of the 2-alkoxy-4-amino-5-chlorobenzamide family possessing a potent serotoninergic or dopaminergic activity has been reported.
Effects of metoclopramide are believed to be due to a combination of a relatively weak serotonin (5-hydroxytryptamine) 5-HT 3 (5-HT 3 ) and dopamine D 2 receptors antagonism and a serotonin 5-HT 4 receptor agonism. The weak affinity and lack of selectivity of metoclopramide for these receptors can be explained by the large number of permissible conformers due to the flexibility of the 2-(diethylamino)ethyl chain. To date, several benzamide derivatives with potent and selective activity for the dopamine D 2 , and the serotonin 5-HT 4 , and 5-HT 3 receptors have been reported. Thus, zacopride, 4) BRL 24682, 5) renzapride, 6 ) SC 53116, 7) and mosapride 8, 9) with a rigid folded framework as the amine moiety showed good affinity for the 5-HT 3 and/or serotonin 5-HT 4 receptors. On the other hand, clebopride, a compound 1, and BRL 25594 having a benzyl group on the nitrogen atom in the amine moiety had high affinity for the dopamine D 2 and D 3 receptors. 10) Several potent and selective 5-HT 3 receptor antagonists such as ondansetron and granisetron have been used clinically to prevent nausea and emesis induced by cancer chemotherapeutic agents such as cisplatin and radiation treatment. [11] [12] [13] [14] The nausea and emesis are common side effects that can cause patients to refuse subsequent chemotherapeutic sessions. 15) On the other hand, dopamine D 2 receptor antagonists such as phenothiazines and butyrophenones are known to be effective in the treatment of emesis and vomiting induced by centrally acting emetic stimuli such as antiparkinsonian drugs, loperamide, apomorphine, and morphine. 16) In addition, the traditional antiemetic agent domperidone, a peripheral dopamine D 2 receptor antagonist, has been shown to be effective for the treatment of chronic upper gastrointestinal distress and the prevention of nausea and vomiting resulting from variety of causes. 17, 18) However, dopamine D 2 receptor antagonists including domperidone are only minimally effective against chemotherapy-or radiationinduced nausea and vomiting. 19) Previously, we reported that the structurally novel 4-amino-N-(1-benzyl-4-methylhexahydro-1,4-diazepin-6-yl)-5-chloro-2-methoxybenzamide (2x) and the corresponding 4-amino-5-chloro-2-ethoxybenzamide (2y) are potent and selective 5-HT 3 receptor antagonists. 20) In the course of our studies on the structure-activity relationships (SARs) of 2x, y, we found that replacement of the benzyl group in the hexahydro-1,4-diazepine ring by an alkyl group results in a significant increase in the dopamine D 2 receptor binding affinity along with a potent 5-HT 3 receptor antagonistic activity. 21) Thus, the combination of a dopamine D 2 and a 5-HT 3 receptor antagonistic activity was seen as a good strategy for the development of effective therapeutic agents for the treatment of nausea and emesis induced by cancer chemotherapeutic agents, radiation treatment, antiparkinsonian drugs, morphine, and variety of causes. These observations led us to modify the alkyl group in the hexahydro-1,4-diazepine ring of 2x, y, and prepare the optically active N- (1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl) benzamides, resulting in the discovery of (R)-5-chloro-N-(1-ethyl- In search of a dopamine D 2 In particular, 82 showed a potent antagonistic activity for both receptors in vivo tests. Optical resolution of the racemate 82 brought about a dramatic change in the pharmacological profile with the (R)-enantiomer exhibiting a strong affinity for both the dopamine D 2 and the 5-HT 3 receptors, while the corresponding (S)-enantiomer had a potent and selective serotonin 5-HT 3 receptor binding affinity. Introduction of the butyl, 2,2,2-trifluoroethyl, 2,2-difluoroethyl, and 2-methoxyethyl groups at the nitrogen atom in the hexahydro-1,4-diazepine ring was performed by reductive alkylation according to the method of Marchini et al. 24) Treatment of 6-acetylamino-1-ethylhexahydro-1,4-diazepine (12) and 6-benzoylamino-1-methylhexahydro-1,4-diazepine (15) prepared by debenzylation of the 6-(protected amino)-hexahydro-1,4-diazepines 11 20) and 14 22) with the corresponding carboxylic acids and NaBH 4 directly gave the 6-(protected amino)hexahydro-1,4-diazepines 13 and 16i-k in moderate to good yield. Deprotection of 13 and 16i-k with aqueous HCl produced the desired amines 8h-k. The 6-amino-1-(3-hydroxypropyl)-4-methylhexahydro-1,4-diazepine (8l) was prepared as follows. Addition of acrolein to 15, followed by reduction of the formyl group with NaBH 4 gave the 1-(3-hydroxypropyl)-4-methylhexahydro-1,4-diazepine (16l). 16l was attempted to hydrolyze with aqueous HCl, but the reaction was unsuccessful. Next, acetylation of the hydroxyl group of 16l, followed by treatment of the resultant 17 with concentrated HCl afforded the amine 8l in 39% overall yield (Chart 2).
Synthesis and Structure-Activity Relationships of 4-Amino-5-chloro-N-(1,4-dialkylhexahydro-1,4-diazepin-6-yl)-2-methoxybenzamide
The optically active 6-amino-1-ethyl-4-methylhexahydro-1,4-diazepines [(R)-and (S)-8a] were prepared from the optically pure 1H-indazol-3-carboxamide (R)-18 and its enantiomer (S)-18 25) as shown in Chart 3. Hydrogenation of (R)-and (S)-18 over Pd/C, followed by reductive ethylation 26) of (R)-and (S)-19 using acetaldehyde and NaBH 4 gave (R)-and (S)-20, which were treated with concentrated HCl to produce the optically pure (R)-and (S)-8a in excellent overall yield.
The preparation of various benzoic acid derivatives is exhibited in Charts 4-6. The 2-alkoxy-5-chlorobenzoic acids 23d-f, 25, 27, 28, 29a, b, 30 were synthesized as follows. Reaction of methyl 4-acetylamino-5-chloro-2-hydroxybenzoate 27) (21) with ally bromide, benzyl bromide, and butyl iodide, followed by alkaline hydrolysis of the resultants 22d-f gave 2-allyloxy-, 2-benzyloxy-, and 2-butoxy-4-amino-5-chlorobenzoic acids (23d-f), respectively. The 5-chloro-2-isopropoxy-4-methylaminobenzoic acid (25) was obtained by methylation of 22c 20) with MeI in the presence of NaH, followed by alkaline hydrolysis of 24 in 72% overall yield. On the other hand, a similar reaction of 22a with EtI produced the 4-(N-acetyl-N-ethyl)amino-5-chloro-2-methoxybenzoic acid 26 instead of the corresponding methyl ester. Alkaline hydrolysis of 26 furnished the corresponding 4-ethylaminobenzoic acid 27. The 4-acetylaminobenzoic ester 22a was treated with 1.2 molar equivalents of NaOH in aqueous MeOH at 60°C for 1 h to give the corresponding 4-acetylaminobenzoic acid 28 in excellent yield. The 4-dimethylaminobenzoic acids 29a, b were directly synthesized by reductive alkylation of 23a, b 28, 29) using HCHO and NaBH 3 CN in moderate yield. Treatment of 23a with a mixture of HCO 2 H and Ac 2 O gave the corresponding 4-formylamino-benzoic acid 30 in 85% yield.
The preparation of the 5-substituted 4-amino-2-ethoxybenzoic acids 33a, b is shown in Chart 5. Reaction of 31 28, 29) with N-bromosuccinimide (NBS) and iodine monochloride (ICl), followed by alkaline hydrolysis of the 5-halogenobenzoic esters 32a, b gave the 5-bromo-and 5-iodo-4-amino-2-ethoxybenzoic acids (33a, b).
The 5-substituted 2-methoxy-4-methylaminobenzoic acids 37a-d, 43 , and 47 were prepared as shown in Chart 6. The 2-methoxy-4-[N-methyl-N-(p-toluenesulfonyl)]aminobenzoic acid (35) was synthesized by modification of the Iwanami et al. method. 30) The salicylic acid derivative 34 30) was treated with ca. 3 molar equivalents of dimethylsulfate in the presence of KOH to produce 35 instead of the corresponding methyl ester in 67% yield. Reaction of 35 with NBS, Nchlorosuccinimide (NCS), ICl, and nitric acid-concentrated H 2 SO 4 mixture afforded the 5-substituted 4-methylamino benzoic acids 36a-d, respectively. Deprotection of 36a-d with concentrated H 2 SO 4 afforded the corresponding 4-methylaminobenzoic acids 37a, b, d, except for the 5-iodobenzoic acid 37c, in excellent yield. As the acidic hydrolysis of 36c eliminates the iodine atom at the 5-position, another route for the preparation of 37c was examined. Treat-ment of the 4-methylamino-2-methoxybenzoic ester 38 30) with Ac 2 O provided the 4-(N-acetyl-N-methyl)aminobenzoic ester 39, which was halogenated with ICl to give 40 in good yield. Instead of acid hydrolysis, alkaline hydrolysis of 40 smoothly proceeded to afford the desired 5-iodo-2-methoxy-4-methylaminobenzoic acid (37c) in 84% overall yield. In order to protect the 4-methylamino group of 38, treatment of 38 with benzyl bromide in the presence of K 2 CO 3 gave the 4-(N-benzyl-N-methyl)aminobenzoic ester 41. Under Vilsmeier reaction conditions, 41 gave an inseparable mixture of the desired 5-formyl-4-methylaminobenzoic ester 42a and the 5-formyl-4-(N-formyl-N-methyl)aminobenzoic ester 42b. Vilsmeier reaction of the moderately reactive benzoic ester 41 caused not only formylation at the 5-position but also concurrent debenzylation at the 4-amino moiety, thereby producing 42a and the further N-formylated product 42b. Alkaline hydrolysis of the mixture of 42a, b produced the single product 43 in 30% yield. On the other hand, reaction of 38 with Br 2 and ammonium thiocyanate, followed by treatment of the resulting 5-thiocyanobenzoic ester 44 with KOH and Et 2 SO 4 gave the 5-ethylthiobenzoic ester 45, although the yield was poor. Alkaline hydrolysis of 45 and successive oxidation of the resultant benzoic acid 46 with hydrogen peroxide afforded the 5-ethylsulfonylbenzoic acid derivative 47 in good yield.
The benzotriazole-and benzimidazole-5-carboxylic acids 51 and 53 were prepared as shown in Chart 7. Introduction of a nitro group at the 3-position of 22a, followed by hydrogenation of the resultant methyl 4-acetylamino-5-chloro-2-methoxy-3-nitrobenzoate (48) over Raney Ni gave the 3-aminobenzoic ester 49. Treatment of 49 with sodium nitrite in acidic solution, and successive acidic hydrolysis of the benzotriazole 50 afforded 7-chloro-4-methoxy-1H-benzotriazole-5-carboxylic acid (51). Reflux of a solution of 49 in the presence of TsOH in toluene gave the benzimidazole-5-carboxylic ester 52, and alkaline hydrolysis of 52 provided the benzimidazole-5-carboxylic acid 53.
The benzamide and carboxamide derivatives 71, 72, 80-82, 85-97, 98-112, 114, 115, 117, 118, 120-123, On the other hand, hydrogenation of 2x over Pd/C gave the debenzylated benzamide 75. The 1-(2-hydroxyethyl)benzamide derivative 96 was derived from the 1-(2-methoxyethyl)-4-methylhexahydro-1,4-diazepine analogue 95 using trimethylsilyl iodide. Treatment of the 6-(tert-butoxycarbonylamino)-2,3-dimethoxybenzoic acid 31) (62) with thionyl chloride followed by condensation of the resultant acid chloride with 8a afforded directly the 6-amino-2,3-dimethoxybenzamide 124 in 49% yield (Chart 9).
The 5-fluoro-2-methoxy-4-methylaminbenzamide 113 was prepared from 2,4,5-trifluorobenzoic acid (63) as shown in Chart 10. Treatment of 63 with N-benzylmethylamine afforded the regioselective 4-(N-benzyl-N-methyl)amino-2,5-difluorobenzoic acid (64) in 49% yield. Condensation of 64 with 8a produced the 4-(N-benzyl-N-methyl)aminobenzamide 65, which was underwent a substitution reaction with NaOMe to provide the 2-methoxy-4-(N-benzyl-N-methyl)-aminobenzamide 66. Hydrogenation of 66 over Pd/C afforded the desired 5-fluorobenzamide 113. NaBH 4 reduction of 115 gave the corresponding 5-hydroxymethylbenzamide 116. The 5-sulfamoylbenzamide 119 was prepared as follows. Introduction of a chlorosulfonyl group at the 5-position of the commercially available 4-chloro-2-methoxybezoic acid (67) was performed by reaction with chlorosulfuric acid. Reaction of the resultant 4-chloro-5-chlorosulfonyl-2-methoxybenzoic acid (68) with 28% aqueous ammonia gave the 5-sulfamoylbenzoic acid 69, which was condensed with 8a to provide the 4-chloro-5-sulfamoylbenzamide (70). Finally, treatment of 70 with MeNH 2 in a sealed tube afforded the desired 119 in 84% yield (Chart 10).
Results and Discussion
The affinity of the benzamide and carboxamide derivatives for the 5-HT 3 receptor in the central nervous system was determined by inhibition of the specific binding of [ 32) Receptor binding data at the 5-HT 3 and the dopamine D 2 receptors for compounds 2x, y, and 71-130 along with those for each enantiomer of 81, 82, 110, and 112 are listed in Table 1 . For comparison, data for metoclopramide, the potent and selective 5-HT 3 receptor antagonist, ondansetron, and the potent and selective dopamine D 2 receptor antagonist, domperidone are included in Table 6 .
Metoclopramide was characterized by its weak affinity for the dopamine D 2 and the 5-HT 3 receptors, while domperidone (15.1 nM) showed a potent affinity for only dopamine D 2 receptor, and ondansetron (1.26 nM) was exhibited a potent affinity for only 5-HT 3 receptor. First, the effects on affinity of a substitution at the 1-and 4-positions in the hexahydro-1,4-diazepine ring of 2x, y leading to 71-97 were examined and the newly prepared benzamides were compared to 2x, y, two potent and selective 5-HT 3 receptor antagonists (serotonin 5-HT 4 33) and dopamine D 2 receptor binding affinities Ͼ1000 nM). Benzamides 71 and 72 having 1-benzyl-4-methylhexahydro-1,4-diazepine ring in the amine moiety, as well as 2x, y, showed a much strong affinity for the 5-HT 3 receptor regardless of the substituent at the 2-alkoxy group in the benzoyl moiety. However, their affinity for the dopamine D 2 receptor was weak (Ͼ1000 nM). Replacement of the methyl group in 2x by an ethyl group (giving 73) resulted in an increase in affinity for the dopamine D 2 receptor (292 nM). On the other hand, the corresponding 2-ethoxybenzamide 74 did not show good affinity for the dopamine D 2 receptor, in spite of a potent 5-HT 3 receptor binding affinity. An interesting increase in the affinity of 73 for the dopamine D 2 receptor led us to prompt further modifications of the substituent in the hexahydro-1,4-diazepine ring. The debenzylated benzamide (75) of 2x exhibited weak affinity for the dopamine D 2 receptor. Though 76-79, having a 1,4-dimethylhexahydro-1,4-diazepine ring, did not display good binding affinity for the dopamine D 2 receptor, the 4-methylamino counterpart 80 showed an enhanced affinity for this receptor. Compound 80 exhibited a binding affinity for the dopamine D 2 receptor ca. 2.5-fold stronger than that of metoclopramide (198 nM vs. 483 nM) along with a potent 5-HT 3 receptor affinity (1.86 nM). Replacement of the benzyl group of 2x, 73, and 74 by an ethyl, propyl, isopropyl, or cyclopropyl group (yielding 81, 83, 84, 86-91) resulted in an increase in the binding affinity for the dopamine D 2 receptor except for 88 with a 1-isopropyl-4-methylhexahydro-1,4-diazepine ring. The affinity of the benzamides prepared for the dopamine D 2 receptor did not depend upon the size of the substituent and 91 with a 1-cyclopropyl-4-ethylhexahydro-1,4-diazepine ring had the most potent affinity (50.3 nM) for this receptor. The affinity of 91 for the dopamine D 2 receptor was ca. 10-fold more potent than that of metoclopramide and ca. 3-fold less potent than that of domperidone. The dopamine D 2 receptor binding site of the substituent in the hexahydro-1,4-diazepine ring is thought to have a spatial narrow pocket with an optimal volume for a methyl, ethyl, or cyclopropyl group. This results are in contrast with those previously reported regarding the recognition of the dopamine D 2 receptor 34) ; i.e. the role of the N-benzyl substitution and the extended shape of the molecule were shown to be important for the recognition of the dopamine D 2 receptor by clebopride, BRL 25594, and other structurally-related dopaminergic antagonists, which displayed high affinity for this receptor. The N-methylamino analogous 82 and 85 increased the binding affinity for the dopamine D 2 receptor compared with the parents 81 and 83, respectively (61.0 nM and 48.4 nM vs. 127 nM and 216 nM, respectively). A similar result has been reported in the SARs study of the antipsychotic drug nemonapride (Fig. 1) , which showed a very strong affinity for the dopamine D 2 receptor; i.e. the 5-chloro-2-methoxy-4-methylaminobenzamide showed a more potent affinity (1 order of magnitude) for the dopamine D 2 receptor than the corresponding 4-aminobenzamide. 30) Benzamides with a butyl group (92) and alkyl substituents having a fluoro (93, 94), methoxy (95), and hydroxy (96, 97) groups exhibited weak affinity for the dopamine D 2 receptor along with a potent 5-HT 3 receptor binding affinity. The presence of a large substituent with oxygen atom and fluorine had an unfavorable effect on the affinity for the , and 91 displayed weak inhibition of apomorphine-induced emesis compared with metoclopramide, although their affinity for the dopamine D 2 receptor was higher than that of metoclopramide. These compounds were, thus, considered to have low oral bioavailability. Therefore, the optimum substituents at the 1-and 4-positions in the hexahydro-1,4-diazepine ring were found to be ethyl and methyl groups, respectively. Next, the influence of a substitution at the 4-and 2-positions in the benzoyl moiety of 81 was examined in detail, while keeping the 1-ethyl-4-methylhexahydro-1,4-diazepine ring constant (98-108). As mentioned above, the 4-methylaminobenzamide derivative 82 showed an increased affinity for the dopamine D 2 receptor with a maintained potent binding affinity for the 5-HT 3 receptor. Replacement of the methyl group of 82 by an ethyl group (yielding 98) and further introduction of a methyl group into the 4-methylamino group of 82 (yielding 99 with 4-dimehylamino group) led to a decrease in the binding affinity for the dopamine D 2 receptor, although the affinity of 98 for the 5-HT 3 receptor was ca. 4-fold stronger than that of the parent 81. The 4-dimethylaminobenzamide derivative 99, on the other hand, showed a decrease in affinity for both the 5-HT 3 and the dopamine D 2 receptors. Introduction of a formyl group (giving 100) weakened the affinity for the dopamine D 2 receptor, but maintained a strong 5-HT 3 receptor binding affinity. In contrast, the 4-acetylamino derivative 101 did not show any affinity for both receptors, although the reason for this was unclear. Replacement of the methoxy group at the 2-position of 81, 82, and 99 by an ethoxy (102, 103), isopropoxy (104, 105), allyloxy (106), benzyloxy (107), or butoxy (108) group tended to significantly decrease the affinity for the dopamine D 2 receptor. Thus, a small substituent, such as a methoxy group at this position, was found to be essential for recognition of the dopamine D 2 receptor. The 5-HT 3 receptor binding affinity of the compounds described above was potent, particularly that of the 2-isopropoxybenzamides 104 and 105 (0.46 nM and 0.75 nM, respectively) which had an affinity much stronger than that of ondansetron (1.26 nM). Thus, for both receptor binding assays, the optimum substituents at the 2-and 4-positions in the benzoyl moiety were found to be methoxy and methylamino groups, respectively. Vol. 50, No. 7 The influence of a substitution at the 5-position in the benzoyl moiety of 82 and 102 was next studied (109-119). Replacement of the chlorine atom of 102 and 82 by a bromine atom (giving 109 and 110) caused a remarkable increase in affinity for both receptors. The 5-bromo-2-methoxy-4-methylaminobenzamide 110, in particular, showed a potent affinity for the dopamine D 2 (35.5 nM) and the 5-HT 3 (2.54 nM) receptors. Replacement of the iodine atom in 102 and 82 (yielding 111 and 112) resulted in an increase in the dopamine D 2 receptor binding affinity but no change in the 5-HT 3 receptor binding affinity. Introduction of fluoro, nitro, formyl, hydroxymethyl, ethylthio, ethylsulfonyl, and sulfamoyl groups at the 5-position (113-119) did not provide any improvements in affinity for both receptors, except for the 5-ethylthiobenzamide 117 (dopamine D 2 receptor binding affinity; 26.1 nM) and the 5-formylbenzamide 115 (5-HT 3 receptor binding affinity; 3.00 nM). From these results, the chlorine, bromine and iodine atoms were found to be optimal substituents at the 5-position in the benzoyl moiety.
The influence of several 2-methoxybenzamides and carboxamide derivatives (120-130) on the affinity for both the dopamine D 2 and the 5-HT 3 receptors was examined. The 5-iodo-2-methoxy (120), 3-bromo-2,6-dimethoxy (121), 3,5-dibromo-2,6-dimethoxy (122), 4-chloro-2-methoxy-5-nitro (123), 6-amino-2,3-dimethoxy (124), 5-bromo-3-chloro-6-hydroxy-2-methoxy (125), 5-ethylthio-2-methoxy (126), 5-ethylsulfonyl-2-methoxy (127), and 5-sulfamoyl-2-methoxy (128) benzamides, and the benzotriazole-(129) and the benzimidazole-(130) 5-carboxamides were examined. All the compounds showed weak affinity for both receptors except 128 which displayed a moderate affinity for the 5-HT 3 receptor (13.7 nM). From these results, the nitrogen atom at the 4-position, the halogeno atom at the 5-position, and the methoxy group at the 2-position in the benzoyl moiety were found to be essential for a potent affinity for both receptors. It is well-known that the pharmacophore for 5-HT 3 receptor antagonists consists of an aromatic ring, a carbonyl group, and a basic nitrogen, and that their location is crucial for the activity. 35) Thus, it is convincing that a number of benzamides, regardless of the nature of the N 1 ,N 4 -disubstituents on the hexahydro-1,4-diazepine ring and the benzoyl moiety, possess nanomolar affinity for the 5-HT 3 receptor and are essentially equipotent to previously described 5-HT 3 receptor antagonists such as ondansetron and granisetron. On the other hand, although no distinct SARs concerning the affinity of benzamides for the dopamine D 2 receptor were identified, 2-methoxy, 4-methylamino, and 5-bromo or iodo groups in the benzoyl moiety provided some improvement in the affinity for this receptor. Table 1 . c) The enantiomeric purity was confirmed to be Ͼ99% ee by HPLC analysis [column; CHIRALPAK AS (DAICEL Chemical Industries, Ltd.), 4.6ϫ250 mm i.d., eluent; hexane/EtOH/Et 2 NHϭ94/6/0.2, flow rate; 0. Although there were marked differences in affinity for the dopamine D 2 receptor between the enantiomers examined, (R)-110 showed the most potent affinity for both receptors (dopamine D 2 receptor; 18.8 nM, 5-HT 3 receptor; 3.40 nM). Moreover, each enantiomer's affinity for both receptors was slightly lower than the dopamine D 2 receptor affinity of domperidone and the 5-HT 3 receptor binding affinity of ondansetron, respectively, and was much stronger than the affinity of metoclopramide for both receptors ( Table 6) .
As for the inhibition of apomorphine-induced emesis in dogs, the results are presented in Table 7 ; the 5-HT 3 receptor antagonistic activity of (R)-82, 2x, ondanstron, and metoclopramide was characterized by an IC 50 ϭ1.4, 0.86, 2.8, and 181 mg/kg, i.v., respectively. From the results above it was, thus, concluded that (R)-82 exhibits a strong affinity for the dopamine D 2 and the 5-HT 3 receptors and a potent antagonistic activity in vivo biological assay for the both receptors. In addition, (R)-82, as well as 2x and 2y, showed a weak binding affinity for the serotonin 5-HT 4 receptor (Ͼ1000 nM) 33) and did not display any serotonin 5-HT 4 receptor agonistic activity even at 10 Ϫ5 M in isolated guinea pig ileum preparations.
Benzamide derivatives with good affinity for the serotonin 5-HT 4 and 5-HT 3 or the serotonin 5-HT 4 and the dopamine D 2 receptors are well-known thus far. 36) However, there has been no report on benzamides having a potent affinity for both the dopamine D 2 and the 5-HT 3 receptors. In this study, we have shown that benzamide 82, a novel dopamine D 2 and 5-HT 3 receptors dual antagonist, is structurally related to the 1-benzyl-4-methyl and 1,4-dimethylhexahydro-1,4-diazepinylbenzamides 2x and 76, which have been described as potent and selective 5-HT 3 receptor antagonists. Moreover, the fact that (R)-82, (S)-82, and 2x had marked structural similarities but different pharmacological profiles, was intriguing. Although the hexahydro-1,4-diazepine ring of 82 is to some extent conformationally restricted compared with the (diethylamino)ethyl side chain of metoclopramide, it still has some degree of conformational freedom. It is speculated that the 1-ethyl-4-methylhexahydro-1,4-diazepine ring of 82 adopts a markedly favorable conformation in the binding site of the dopamine D 2 and the 5-HT 3 receptors where one or two basic nitrogen atoms and the ethyl and/or methyl groups occupy the correct orientation to block both receptors. The role of the substituents in the hexahydro-1,4-diazepine ring in the recognition of these compounds by the dopamine D 2 and the 5-HT 3 receptors and structural analysis of the differences in the pharmacological profile between each enantiomer are in progress.
In summary, replacement of the 1-benzyl group in the hexahydro-1,4-diazepine ring of 2x, a potent and selective 5-HT 3 receptor antagonist, by an ethyl group resulted in a remarkable increase in affinity for the dopamine D 2 receptor, while keeping a potent 5-HT 3 receptor binding affinity. After modification of the 4-amino-5-chloro-2-methoxybenzoyl moiety of the 1-ethyl-4-methylhexahydro-1,4-diazepinylbenzamide 81, the corresponding 4-methylaminobenzamide 82 was found to have strong antagonistic activity, both in vitro (binding affinity for the dopamine D 2 and the 5-HT 3 receptors) and in vivo (inhibition of apomorphine-induced emesis and the von Bezold-Jarisch reflex induced 2-methyl-5-HT) tests. Optical resolution of 82 brought about a drastic change in the binding affinity for the dopamine D 2 receptor, particularly, the (R)-enantiomer [(R)-82] exhibited an affinity for the dopamine D 2 receptor ca. 2-fold that of 82, while (S)-82 was found to have a weaker affinity for this receptor. On the other hand, the binding affinity for the 5-HT 3 receptor of each enantiomer [(R)-82, (S)-82] was ca. 2 times more potent than that of the racemate 82. Although 82 and its enantiomers showed a significant difference in the binding affinity for the dopamine D 2 and the 5-HT 3 receptors, (R)-82, which constitute a novel amine moiety of the 4-amino-5-chloro-2-methoxybenzamide family, exhibited a potent dual antagonistic activity for the dopamine D 2 and the 5-HT 3 receptors and is expected to be a broad antiemetic agent.
Experimental
All melting points were determined on a Yanagimoto micromelting point apparatus without correction. IR spectra were recorded on a Shimadzu FTIR-8200PC spectrometer with KBr disks unless otherwise stated. Electron ionization and atmospheric pressure chemical ionization mass spectra were obtained on a JEOL JMS D-300 and Hitachi M-1000 spectrometer, respectively. 1 H-NMR spectra were recorded on a Varian Gemini-200 (200 MHz) or a JEOL JNM-LA300 (300 MHz) spectrometer using dilute solution in CDCl 3 unless otherwise stated. Chemical shifts were expressed as d (ppm) value from tetramethylsilane as an internal standard and coupling constants (J) are given in Hz. Optical rotations were measured at 589 nm with a Jasco P-1020 digital polarimeter. Organic extracts were dried over anhydrous MgSO 4 or anhydrous Na 2 SO 4 . The solvents were evaporated under reduced pressure. Flash chromatography was carried out on 60 mm mesh silica gel (Fuji Silysia FL60D).
The following known 6-aminohexahydro-1,4-diazepines and benzoic acids were prepared according to the cited literature: 6-amino-1-benzyl-4-methylhexahydro-1,4-diazepine 23, 37) (61). Methyl 4-acetylamino-5-chloro-2-methoxybenzoate (22a), 4-amino-5-chloro-2-methoxybenzoic acid (23a), 2,4,5-trifluorobenzoic acid (63), and 4-chloro-2-methoxybenzoic acid (67) are commercially available. N-Ethyl-N-methylethylenediamine (5a) SOCl 2 (267 g, 2.2 mol) was added dropwise to a solution of 2-(ethylamino)ethanol (3m, 100 g, 1.1 mol) in CHCl 3 (845 ml) kept at ca. 0°C. The mixture was heated to reflux for 6 h and cooled to room temperature. The reaction mixture was poured into Et 2 O (ca. 1000 ml), and the whole was stirred at room temperature for 15 h. In order to decompose the excess of SOCl 2 , excess EtOH was added slowly to the solution at ca. 0°C. The resulting powder was collected by filtration, washed with Et 2 O, and dried to give 150 g (93%) of N-(2-chloroethyl)-Nethylamine hydrochloride (4m), which was used in the next step without further purification. 4m (100 g, 0.69 mol) was added portionwise to a mixture of 40% aqueous MeNH 2 (700 ml), EtOH (150 ml), and H 2 O (600 ml) kept at 10°C. The mixture was heated at 50°C for 16 h and cooled to room temperature. After addition of a large amount of solid K 2 CO 3 , the upper layer was separated. EtOH was evaporated under atmospheric pressure, and the residue was dissolved in CH 2 Cl 2 . The organic solution was dried over anhydrous Na 2 SO 4 and evaporated at ca. 35°C to leave a pale brown oil, which was distilled to give 50.0 g (71%) of 5a as a colorless oil, bp 30 
. N-Ethyl-N-propylethylenediamine (5e) In a similar manner to that described above, crude 5e was obtained by the reaction of 4m (24.0 g, 0.17 mol) with PrNH 2 (150 ml, 1.8 mol) in EtOH (20 ml)-H 2 O (100 ml) mixture in 35% yield as a pale yellow oil. Crude 5e was used in the next step without distillation. was added dropwise to a solution of 2-(propylamino)ethanol (3n, 41.0 g, 0.40 mol) in CHCl 3 (300 ml) kept at ca. 0°C. The mixture was heated to reflux for 6 h and cooled to room temperature. The reaction mixture was concentrated to dryness. A mixture of i PrOH and Et 2 O was added carefully to the solid residue at ca. 0°C. The resulting powder was collected by filtration, washed with Et 2 O, and dried to give 20.3 g (32%) of N-(2-chloroethyl)-N-propylamine hydrochloride (4n) as a white powder, which was used in the next step without further purification. In a similar manner to that described above, crude 5b was obtained from the reaction of 4n (20.0 g, 0.13 mol) with 40% aqueous MeNH 2 (130 ml) in EtOH (120 ml) in 45% yield as a colorless oil and used in the next step without distillation. 1 
. N-Ethyl-N-isopropylethylenediamine (5f) SOCl 2 (182 g, 1.5 mol) was added dropwise to a solution of 2-(isopropylamino)ethanol (3o, 75.0 g, 0.73 mol) in CHCl 3 (550 ml) kept at ca. 0°C. The mixture was heated to reflux for 6 h and cooled to room temperature. After addition of Et 2 O, the mixture was stood overnight at room temperature. The resulting powder was collected by filtration, washed with Et 2 O, and dried to give 114 g (99%) of N-(2-chloroethyl)-N-isopropylamine hydrochloride (4o) as a hygroscopic brown powder, which was used in the next step without further purification. In a similar manner to that described above, 5f was obtained from the reaction of 4o (57.0 g, 0.36 mol) with 70% aqueous EtNH 2 (340 ml) in EtOH (350 ml) in 26% yield as a colorless oil, bp 41-43°C/5 mmHg. . N-Cyclopropyl-N-methylethylenediamine (5d) SOCl 2 (332.5 g, 2.8 mol) was added dropwise to a solution of 2-(methylamino)ethanol (3l, 100 g, 1.3 mol) in CHCl 3 (1000 ml) kept at ca. 0°C. The mixture was heated to reflux for 6 h and cooled to room temperature. The reaction mixture was poured into Et 2 O (ca. 1500 ml) and stirred at room temperature for 15 h. In order to decompose the excess of SOCl 2 , a large amount of EtOH was added carefully to the solution at ca. 0°C. The resulting powder was collected by filtration, washed with Et 2 O, and dried to give 165 g (95%) of N-(2-chloroethyl)-N-methylamine hydrochloride (4l), which was used in the next step without further purification. 4l (53.0 g, 0.41 mol) was added portionwise to a mixture of cyclopropylamine (282 ml, 4.1 mol) and EtOH (470 ml) kept below 10°C. The mixture was heated at 50°C for 16 h and cooled to room temperature. After addition of a large amount of solid K 2 CO 3 , the upper layer was separated. EtOH was evaporated under atmospheric pressure, and the resultant residue was dissolved in CH 2 Cl 2 . The organic solution was dried over anhydrous Na 2 SO 4 and evaporated at ca. 35°C to leave a pale brown oil, which was distilled to give 25.4 g (55%) of 5d as a colorless oil, bp 35-38°C/ca. 20 mmHg. 
. 6-Amino-1-ethyl-4-methylhexahydro-1,4-diazepine (8a) Our previously described procedure 22) was adopted. 1) To a solution of 2-benzyloxycarbonylaminopropenal 23) (6, 3.8 g, 19 mmol) in MeOH (50 ml) was added 5a (3.8 g, 37 mmol) at ca. 5°C. After being stirred for 3 h, NaBH 4 (2.8 g, 74 mmol) was added portionwise. The mixture was stirred at room temperature for 16 h and then concentrated to dryness. The residue was taken into CHCl 3 and H 2 O. The organic layer was separated, washed with brine, and dried over anhydrous MgSO 4 . The solvent was evaporated, and the residue was chromatographed on silica gel with CHCl 3 /MeOHϭ10/1 to give 2.5 g (46% from 6) of 6-benzyloxycarbonylamino-1-ethyl-4-methylhexahydro-1,4-diazepine (7a) as an oil.
1 H- Amino-1-methyl-4-propylhexahydro-1,4-diazepine (8b) In a similar manner to that described above, 8b was prepared from 5b and 6 via 6-benzyl- -1-ethyl-4-propylhexahydro-1,4-diazepine (8e) In a similar manner to that described above, 8e was prepared from 5e and 6 via 6-benzyloxycarbonylamino-1-ethyl-4-propylhexahydro-1,4-diazepine (7e) in 30% overall yield. 7e; -1-ethyl-4-isopropylhexahydro-1,4-diazepine (8f) 1) 5f (6.0 g, 46 mmol) was added to a solution of trishydroxymethylnitromethane (7.4 g, 49 mmol) and NaHCO 3 (2.5 g) in H 2 O (50 ml) at room temperature. The mixture was stirred at 40-50°C for 2 h and cooled to ca. 10°C. The resulting oil was extracted with CH 2 Cl 2 . The extract was washed with brine and evaporated at ca. 25°C. The oily residue containing 1-ethyl-6-hydroxymethyl-4-isopropyl-6-nitrohexahydro-1,4-diazepine (9f) was dissolved in MeOH, and potassium tert-butoxide (5.8 g, 52 mmol) was added portionwise below 50°C. The mixture was stirred at the same temperature for 0.5 h and concentrated to dryness at 40-50°C. After slow addition of a solution of NH 2 OH · HCl (95%, 3.6 g, 49 mmol) in H 2 O (24 ml), the mixture was extracted with CH 2 Cl 2 . The extract was washed with brine and evaporated. The oily residue was chromatographed on silica gel with AcOEt to give 4.3 g (43% from 5f) of 1-ethyl-4-isopropyl-6-nitrohexahydro-1,4-diazepine (10f) as a pale yellow oil. . 2) A solution of 10f (4.3 g, 20 mmol) in EtOH (20 ml) was hydrogenated over Raney Ni (ca. 1 g) at room temperature for 3 h. The catalyst was removed by Celite filtration, and the filtrate was concentrated. The residue was dissolved in CHCl 3 , and the solution was dried over anhydrous MgSO 4 . The solvent was evaporated to give 3.2 g (86%) of 8f as a pale yellow oil, which was used in the next step without further purification.
6-
oxycarbonylamino-1-methyl-4-propylhexahydro-1,4-diazepine (7b) in
6-Amino-1-isopropyl-4-methylhexahydro-1,4-diazepine (8c)
In a similar manner to that described above, 8c was prepared from trishydroxymethylnitromethane and 5c via 9c and 1-isopropyl-4-methyl-6-nitrohexahydro-1,4-diazepine (10c) in 7% overall yield. 10c (pale yellow oil); 45, 46) was applied. A solution of 6-acetylamino-1-benzyl-4-ethylhexahydro-1,4-diazepine 20) (11, 20.1 g, 73 mmol) and 1-chloroethyl chloroformate (12.6 g, 88 mmol) in 1,2-dichloroethane (200 ml) was heated to reflux for 1 h and cooled to room temperature. After evaporation of the solvent, the residue was dissolved in MeOH (200 ml). The solution was heated to reflux for 1 h and cooled to room temperature. The solvent was evaporated, and the residue was dissolved in a small volume of H 2 O. The aqueous solution was basified with 48% aqueous NaOH. After addition of solid K 2 CO 3 , the mixture was extracted with CHCl 3 . The extract was concentrated to dryness, and the oily residue was chromatographed on silica gel with CHCl 3 /MeOHϭ15/1 to give 12.3 g (91%) of 6-acetylamino-1-ethylhexahydro-1,4-diazepine (12) 
. 2) 12 (2.0 g, 11 mmol) and NaBH 4 (2.1 g, 56 mmol) were added successively to a solution of butyric acid (15.7 g, 0.18 mol) in anhydrous toluene (27 ml) below 20°C. The mixture was heated to reflux for 3 h and cooled to room temperature. The reaction mixture was washed with 2 N aqueous NaOH and dried over anhydrous MgSO 4 . The solvent was evaporated, and the residue was chromatographed on silica gel with CHCl 3 /MeOHϭ10/1 to give 2.0 g (77%) of 6-acetylamino-1-butyl-4-ethylhexahydro-1,4-diazepine (13) -1-methyl-4-(2,2,2-trifluoroethyl)hexahydro-1,4-diazepine (8i)  1) A solution of 14 22) (24.3 g, 75 mmol) in EtOH (400 ml)-AcOH (40 ml) mixture was hydrogenated over 10% Pd/C (3.5 g) at ca. 50°C under atmospheric pressure. After no further change in the pressure of H 2 was observed, the solution was cooled to room temperature. The catalyst was filtered through Celite, the filtrate was concentrated, and the oily residue was dissolved in CHCl 3 . The solution was washed successively with 10% aqueous NaHCO 3 , brine, and dried over anhydrous MgSO 4 . The solvent was evaporated to give 16.3 g (93%) of N-(1-methylhexahydro-1,4-diazepin-6-yl ). 3) A solution of 16i (1.5 g, 4.8 mmol) in 35% aqueous HCl (10 ml) was heated to reflux for 8 h and cooled to room temperature. The reaction mixture was washed with Et 2 O and basified with 48% aqueous NaOH. After addition of solid K 2 CO 3 , the mixture was extracted with CHCl 3 . The extract was evaporated to give 1.0 g (quantitative yield) of 8i as a pale yellow oil.
6-Amino

6-Amino-1-(2,2-difluoroethyl)-4-methylhexahydro-1,4-diazepine (8j)
In a similar manner to that described above, the reaction of 15 with CF 2 HCO 2 H and NaBH 4 gave N-[1-(2,2-difluoroethyl)-4-methylhexahydro-1,4-diazepin-6-yl]benzamide (16j) in 63% yield. . In a similar manner to that described above, 16j was converted into the corresponding amine 8j in quantitative yield as an oil.
6-Amino-1-(2-methoxyethyl)-4-methylhexahydro-1,4-diazepine (8k)
In a similar manner to that described above, the reaction of 15 with 2-methoxyacetic acid and NaBH 4 
gave N-[1-(2-methoxyethyl)-4-methylhexa-
. In a similar manner to that described above, 16k was converted into the corresponding amine 8k in quantitative yield as an oil.
6-Amino-1-(3-hydroxypropyl)-4-methylhexahydro-1,4-diazepine (8l) 1) Acrolein (90%, 3.6 g, 58 mmol) was added to a solution of 15 (5.0 g, 21 mmol) and Et 3 N (6.5 g, 64 mmol) in MeOH (50 ml) at ca. 0°C. The mixture was stirred at this temperature for 2 h. Then, NaBH 4 (4.9 g, 0.13 mol) was added portionwise at ca. 0°C, and the mixture was stirred at this temperature for 1 h and at room temperature overnight. After evaporation of the solvent, the residue was taken into H 2 O and CHCl 3 . The organic layer was separated, washed with brine, and dried over anhydrous 25) [(R)-18, Ͼ99.5% ee, 28.8 g, 76 mmol] in EtOH (500 ml) was hydrogenated over 10% Pd/C (4.3 g) at room temperature under H 2 atmosphere. After no further change in the pressure of H 2 was observed, the catalyst was filtered through Celite. The filtrate was concentrated to dryness to give 20.9 g (quantitative yield) of (R)-N- (1-methylhexahydro-1,4-diazepin-6-yl) (16.0 g, 0. 16 mol) in MeOH (500 ml) under ice-cooling. The mixture was stirred at the same temperature for 2 h. Then, NaBH 4 (3.0 g, 79 mmol) was added portionwise to the reaction mixture at this temperature. The whole was warmed to room temperature, stirred for 16 h, and concentrated to dryness. The residue was taken into H 2 O and CHCl 3 , and the organic layer was separated, washed with brine, and dried over anhydrous aqueous HCl (70 ml) was heated to reflux for 8 h and cooled to ca. 5°C. The resulting solid of 1H-indazole-3-carboxylic acid was filtered off and the filtrate was basified with 48% aqueous NaOH. After addition of solid K 2 CO 3 , the mixture was extracted with CHCl 3 . The extract was evaporated to give ca. 11 g (quantitative yield) of (R)-8a as a pale yellow oil, which was used in the next step without further purification. This compound was identical to the sample obtained in an alternative preparation, 47) on the basis of 1 H-NMR, MS, and the retention time of chiral HPLC comparison.
g (61%) of N-[1-(3-acetoxypropyl)-4-methylhexahydro-1,4-diazepin-6-yl]benzamide
). (R)-and (S)-6-Amino-1-ethyl-4-methylhexahydro-1,4-diazepines [(R)-and (S)-8a] 1) A solution of (R)-
In a similar manner to that described for the conversion of (R)-18 to (R)-8a, (S)-8a was prepared from (S)-18, 25) the hydrochloride of (S)-19; mp 241-245°C (EtOH). Anal. Calcd for C 14 , and methyl ethyl ketone (100 ml) was heated to reflux for 9 h and cooled to room temperature. The solvent was evaporated, and the residue was dissolved in H 2 O and CHCl 3 . The organic layer was separated, washed with brine, and dried over anhydrous MgSO 4 . The solvent was evaporated, and the oily residue was solidified on standing at room temperature. The solid was triturated with EtOH/Et 2 O to give 1.9 g (33%) of methyl 4-acetylamino-2-allyloxy-5-chlorobenzoate (22d) as a colorless crystal, mp 110.5-112°C. 1 5-Chloro-4-ethylamino-2-methoxybenzoic Acid (27) 1) Methyl 4-acetylamino-5-chloro-2-methoxybenzoate (22a, 10.0 g, 39 mmol) was added portionwise to a suspension of NaH (60% dispersion in mineral oil, 4.7 g, 0.12 mol) in anhydrous tetrahydrofuran (THF) (75 ml) under ice-cooling. The mixture was warmed to room temperature and stirred for 1 h. After the mixture was recooled to ca. 5°C, EtI (31 ml, 0.39 mol) was added, and the whole was stirred at room temperature overnight. The reaction mixture was poured carefully into cold H 2 O, and the volatiles were evaporated. The aqueous solution was washed with CHCl 3 , acidified with 35% aqueous HCl, and extracted with CHCl 3 . The extract was washed with brine and concentrated to dryness to give ca. 10 g of 4-(N-acetyl-N-ethyl)amino-5-chloro-2-methoxybenzoic acid (26) as a pale yellow amorphous solid, which was used in the next step without further purification. 19 mol) and NaOH (9.0 g, 0.23 mol) in a mixture of MeOH (80 ml) and H 2 O (150 ml) was heated at 60°C for 1 h and cooled to room temperature. After evaporation of MeOH, the resulting aqueous solution was acidified with 35% aqueous HCl. The precipitates were collected by filtration and dissolved in MeOH. The solution was concentrated, and the crystalline precipitates were collected by filtration and dried to give 39.6 g (84%) of 28 as a colorless crystal, mp 210-213°C. 5-Chloro-4-dimethylamino-2-ethoxybenzoic Acid (29b) A mixture of 4-amino-5-chloro-2-ethoxybenzoic acid 28) (23b, 2.6 g, 12 mmol), HCHO (37% solution in H 2 O, 8 ml, 0.11 mol), NaBH 3 CN (95%, 1.9 g, 27 mmol), and MeCN (40 ml) was stirred at room temperature for 6 h. After addition of HCHO (37% solution in H 2 O, 4 ml, 54 mmol) and NaBH 3 CN (95%, 1.0 g, 14 mmol), the mixture was restirred at room temperature for 16 h. The solvent was evaporated, and the residue was acidified with 10% aqueous HCl. The precipitates were collected by filtration and recrystallized from EtOH to give 1.7 g (58%) of 29b as a white crystal, mp 144-145°C. : 3294, 1717, 1605, 1406, 1238. 5-Chloro-4-dimethylamino-2-methoxybenzoic Acid (29a) In a similar manner to that described above, 29a (colorless crystal) was prepared from 4-amino-5-chloro-2-methoxybenzoic acid (23a) in 55% yield, mp 150-151.5°C. 2) A mixture of 32a (4.1 g, 13 mmol), NaOH (3.5 g, 88 mmol), MeOH (12 ml), and H 2 O (16 ml) was heated to reflux for 4 h and cooled to ca. 5°C. The reaction mixture was acidified with 25% aqueous H 2 SO 4 , and the precipitates were collected by filtration and recrystallized from MeOH to afford 3.3 g (98%) of 33a as a colorless crystal, mp 179-181°C. 4-Amino-2-ethoxy-5-iodobenzoic Acid (33b) 1) A solution of 31 (5.0 g, 21 mmol) and ICl (3.8 g, 23 mmol) in DMF (25 ml) was stirred at room temperature for 0.5 h, heated at 80°C for 2 h, and cooled to room temperature. After addition of H 2 O (100 ml), the precipitates were collected by filtration and recrystallized from acetone to give 3.6 g (47%) of methyl 4-acetylamino-2-ethoxy-5-iodobenzoate (32b) as a colorless fine needle, mp 188-189°C. 42 (1H, s), 7.93 (1H, s), 11.75 (1H, br s) . 
Anal.
Calcd for C 9 H 10 INO 3 : C, 35.20; H, 3.28; I, 41.33; N, 4.56. Found: C
2-Methoxy-4-[N-methyl-N-(p-toluenesulfonyl)]aminobenzoic Acid (35)
A mixture of 4-(p-toluenesulfonyl)aminosalicylic acid 30) (34, 250 g, 0.81 mol), acetone (1700 ml), and KOH (239 g, 4.3 mol) was stirred at room temperature for 20 min. Me 2 SO 4 (339 g, 2.7 mol) was added dropwise to the mixture at a rate that maintained boiling. The whole was heated to reflux for 2 h and cooled to room temperature. After evaporation of the solvent, the residue was dissolved in H 2 O and washed with AcOEt. The aqueous solution was acidified with 35% aqueous HCl, and the precipitates were collected by filtration, washed with H 2 O, and dried to give 183 g (67%) of 35. An analytic sample of 35 was obtained by recrystallization from acetone as a colorless prism, mp 136-137°C.
1 H-NMR (DMSO-d 6 ) d: 2.48 (3H, s), 2.17 (3H, s), 3.72 (3H, s), 6.73 (1H, dd, Jϭ2.0, 8.5), 6.86 (1H, d, Jϭ2.0),  7.35-7.52 (4H, m), 7.59 (1H, d, Jϭ8.5), 12.50 (1H, s, CO 2 H) . Anal. Calcd for C 16 5-Chloro-2-methoxy-4-methylaminobenzoic Acid (37b) In a similar manner to that described above, 37b was obtained from 5-chloro-2-methoxy-4-[N-methyl-N-(p-toluenesulfonyl)]aminobenzoic acid (36b), which was prepared from 35 using N-chlorosuccinimide (NCS). 36b; mp 210. 5 2-Methoxy-4-methylamino-5-nitrobenzoic Acid (37d) In a similar manner to that described above, 2-methoxy-4-[N-methyl-N-(p-toluenesulfonyl)]amino-5-nitrobenzoic acid (36d) was prepared from 35 using fuming HNO 3 (38, 4 .0 g, 21 mmol), Ac 2 O (10 ml, 0.11 mol), and Et 3 N (1 ml) was stirred at room temperature for 15 h. The reaction mixture was diluted with H 2 O, and then extracted with AcOEt. The extract was washed with brine and concentrated to dryness. The residue was chromatographed on silica gel with AcOEt to give 4.7 g (97%) of methyl 4-(N-acetyl-N-methyl)amino-2-methoxybenzoate (39) as a colorless oil, which was used in the next step without further purification. 1 : 2941, 1676, 1601, 1435, 1387, 1298, 1254. 2) POCl 3 (4.9 g, 32 mmol) was added dropwise to DMF (8.2 ml, 0.11 mol) under ice-cooling. The mixture was warmed to room temperature and stirred for 0.5 h. After addition of 41 (2.8 g, 9.8 mmol), the whole was heated at 80°C for 4 h and cooled to room temperature. The reaction mixture was poured into ice H 2 O (80 ml). Then, AcONa (25 g ) and H 2 O (62 ml) were added, and the mixture was extracted with AcOEt. The extract was washed with brine and concentrated. The resulting insoluble materials were filtered off, and the filtrate was chromatographed on silica gel with AcOEt to afford 0.75 g of an unseparatable mixture of methyl 5-formyl-2-methoxy-4-methylaminobenzoate (42a) and methyl 5-formyl-4-(N-formyl-N-methyl)-amino-2-methoxybenzoate (42b). 3 g, 23 mmol), and MeOH (100 ml) was heated to reflux for 1 h and cooled to room temperature. After addition of Et 2 SO 4 (2.3 g, 15 mmol), the whole was heated to reflux for 48 h and cooled to room temperature. The solvent was evaporated, and the residue was diluted with H 2 O and acidified with 35% aqueous HCl. After addition of CHCl 3 , the insoluble materials were filtered off. The organic layer of the filtrate was separated, washed with brine, and concentrated to dryness. The residue was chromatographed on silica gel with CHCl 3 /AcOEtϭ50/1 to give 1.7 g (34%) of methyl 5-ethylthio-2-methoxy-4-methylaminobenzoate (45) as an oil, which was used in the next step without further purification. 1 (20 ml ) at room temperature under N 2 atmosphere. After being stirred for 6 h, TMSI (0.4 ml, 2.8 mmol) was added. The mixture was stirred at this temperature overnight. MeOH was carefully added to the reaction mixture, and the volatiles were evaporated. The residue was dissolved in CHCl 3 , and the solution was washed successively with saturated aqueous NaHCO 3 , aqueous Na 2 S 2 O 3 , and brine and dried over anhydrous MgSO 4 . After evaporation of the solvent, the residue was chromatographed on silica gel with CHCl 3 /MeOHϭ10/1 to give 0.6 g (62%) of 96 as a pale yellow oil, which was converted into the oxalate in the usual manner. : 3422, 1630, 1508. 3) A mixture of 65 (1.9 g, 4.6 mmol), NaOMe (powder, 0.8 g, 15 mmol), and anhydrous DMF (20 ml) was heated at 120°C for 15 h and cooled to room temperature. After evaporation of the solvent, the residue was taken into H 2 O and CHCl 3 . The organic layer was separated, washed with brine, and dried over anhydrous MgSO 4 . The solvent was evaporated, and the residue was chromatographed on silica gel with CHCl 3 /MeOHϭ 10/1 to give 1.5 g (77%) of 4-(N-benzyl-N-methyl)amino-N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)-5-fluoro-2-methoxybenzamide (66) as a pale yellow oil. 1 8 mmol), EtOH (10 ml), and AcOH (10 ml) was hydrogenated over 10% Pd/C (0.12 g) at 50°C for 2 h under atmospheric pressure. The catalyst was filtered through Celite, and the filtrate was concentrated to dryness. After addition of saturated aqueous NaHCO 3 , the mixture was extracted with CHCl 3 . The extract was washed with brine and concentrated to dryness. The residue was chromatographed on silica gel with CHCl 3 /MeOHϭ10/1 to give 0.7 g (74%) of 113 as a pale yellow oil, which was converted into the maleate in the usual manner. : 1703, 1684, 1587, 1389, 1254. 2) To 28% aqueous NH 3 (50 ml) was added 68 (12.0 g, 42 mmol) in small portions under ice-cooling. The mixture was warmed to 40-50°C and stirred for 2 h at this temperature. After being cooled to ca. 5°C, the reaction mixture was acidified with 35% aqueous HCl. The solid was collected by filtration, washed with H 2 O, and dried to give 10.0 g (89%) of 4-chloro-2-methoxy-5-sulfamoylbenzoic acid (69) as a white powder, mp 224-226°C. 1 (20 ml) was stirred at room temperature for 4 h. The reaction mixture was concentrated to dryness, and the residue was dissolved in H 2 O and washed with Et 2 O. After addition of 2 N aqueous NaOH and solid K 2 CO 3 , the mixture was extracted with CHCl 3 . The extract was concentrated to dryness, and the residue was chromatographed on silica gel with CHCl 3 /MeOHϭ9/1 to 7/1 to give 1.6 g (62% from 69) of 4-chloro-N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)-2-methoxy-5-sulfamoylbenzamide (70) as a pale yellow amorphous solid. 1 Amino-2,3-dimethoxy-N-(1-ethyl-4-methylhexahydro-1,4 -diazepin-6-yl)benzamide 7/4 Oxalate (124) SOCl 2 (0.36 ml, 4.9 mmol) was added to a suspension of 6-(tert-butoxycarbonyl)amino-2,3-dimethoxybenzoic acid (62, 0.9 g, 3.0 mmol), DMF (1 drop), and toluene (20 ml) at room temperature. The mixture was heated at 60°C for 1.5 h and cooled to room temperature. The volatiles were evaporated, and the residue was dissolved in toluene. The solvent was then reevaporated and the oily residue was used in the next step without further purification. A solution of the oil obtained above in CHCl 3 (20 ml) was added dropwise to a solution of 8a (0.48 g, 3.1 mmol) in CHCl 3 (10 ml) under ice-cooling. The mixture was stirred at room temperature for 3 h, washed successively with H 2 O, saturated aqueous NaHCO 3 , and brine, and dried over anhydrous MgSO 4 . After evaporation of the solvent, the residue was chromatographed on silica gel with CHCl 3 /MeOHϭ10/1 to afford 0.5 g (49%) of 124 as a brown oil. The oil was converted into the oxalate in the usual manner. 
(R)-and (S)-81, (R)-and (S)-82, (R)-and (S)-110, (R)-and (S)-112]
A mixture of the benzoic acid derivative or 1H-benzotriazole-and 1H-benzimidazole-5-carboxylic acids (10 mmol), amine (11 mmol), EDC (12 mmol), and CH 2 Cl 2 (80 ml) was stirred at room temperature for 4-5 h. The reaction mixture was washed successively with H 2 O, 10% aqueous NaOH, and brine, and dried over anhydrous MgSO 4 . The solvent was evaporated, and the residue was chromatographed on silica gel. The free base thus obtained was recrystallized from the solvent shown in Tables  1-5 or converted into the fumarate, the maleate, or the oxalate in the usual manner, followed by recrystallization from the solvent shown in Tables 1-5 . Physical data for the benzamide and the carboxamide derivatives are listed in Tables 1-5 .
Binding Assays for Dopamine D 2 and 5-HT 3 Receptors The binding assays for the dopamine D 2 and the 5-HT 3 receptors were carried out according to the method described in previous papers. 20, 32) Effect on Apomorphine-Induced Emesis in Dogs 48) Male beagle dogs, weighing 10-16 kg, were used. Groups of three to six dogs received a subcutaneous injection of apomorphine hydrochloride (0.3 mg/kg) 2 h after pretreatment with test compounds (1.0 mg/kg, p.o.). Emesis inhibition was evaluated by the frequency of emetic episodes 1 h after treatment with apomorphine hydrochloride.
